Inventor						MADEMAH					
	azi et al. Invention	ary out the e	to a figural property of the same	magne i ta ada			و د ایش د و	· • ·		e e e e e e e e e e e e e e e e e e e	
SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME											
TO THE COMMISSIONER FOR PATENTS											
Transmitted herewith is a <u>Statement According to 37C.F.R.</u> § 1.821(f); copy of <u>Sequence Listing in computer readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or <u>Amino Acid Sequence Disclosures and return postcard</u>.</u>											
	Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.										
	A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.										
	Petition for amonth extension of time.										
$\boxtimes$	No additional fee is required.										
	The fee has be	en calculate	d as shown below	v:							
	Small En						Entity	Other Than Small Entity			
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Add'I Fee	or	Rate	Add'l Fee	
Total	Ì	Minus			] [	x \$9=			x \$18=		
Indep. ,	1	Minus		÷		x 42=		] .	x \$84=		
First Presentation of Multiple Dep. Claim									+ \$280=		
						Total add'I fee	\$		Total add'l fee	\$	
	Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ A duplicate copy of this sheet is enclosed.										
	A check in the amount of \$ to cover the filing fee is enclosed.										
	The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.										
	I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.										
			<b>\</b>	Respectfully Gregory M. Registration Agent for A	Zink No.	2 jul 1, p1.D. 48,492					


BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no. EL 562415205US, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

Date: a m

Signature

Normal and the



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
WWW.USDIO.GOV

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/902,736

07/10/2001

Avi Ashkenazi

P1618P2C45

**CONFIRMATION NO. 1517** 

FORMALITIES LETTER

Paul E. Rauch, Ph.D. Brinks, Hofer, Gilson & Lione NBC Tower - Suite 3600 455 Cityfront Plaza Drive Chicago, IL 60611-5599



Date Mailed: 11/21/2001

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

A request to transfer the computer readable form from another application on file at the U.S. Patent and
Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be
complied with since there is no compliant CRF present at the United States Patent and Trademark Office.
Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a
statement that the content of the sequence listing information recorded in computer readable form is
identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new
matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- · To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Sérvice Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE